Skip to main content
Accession Therapeutics Limited

Accession Therapeutics Limited Rating A · Worker

Accession Therapeutics Limited is a healthcare company developing targeted and potent immuno-oncology cancer treatments.

Healthcare Abingdon Website ↗

The UK Home Office lists Accession Therapeutics Limited as a licensed sponsor (A-rated, Skilled Worker route). They can sponsor work visas. We read every advert and list only roles that don't rule out sponsorship. We're showing 1 of their current openings.

Sponsor licence details

Sourced from the UK Home Office register of licensed sponsors.

Licence rating
A
Worker · Active
Licensed
Since at least 2022
Headcount
11-50
39 total
Open roles
1
Live on SponsorJobs
Sector
Healthcare
Location
Abingdon
Visa route
Skilled Worker

Sponsorship history

Certificates of Sponsorship Accession Therapeutics Limited assigned each year, from Home Office figures released under the Freedom of Information Act.

2021
0
2022
1–5
2023
0
2024
1–5
2025
—

Skilled Worker and Global Business Mobility routes. One certificate is assigned for each sponsored hire, visa extension or change of employer, so a person can be counted more than once. “1–5” is withheld by the Home Office; the 2025 figures list only sponsors with 5 or more (“—”). Matched to this employer by its name on the sponsor register. Sources: FOI 2025/12841 (2021–24), FOI2026/03501 (2025). Contains public sector information licensed under the Open Government Licence v3.0.

Licence timeline Pro

Every change we've seen on the Home Office register for Accession Therapeutics Limited, and what its recent adverts say about sponsorship.

See this employer's full licence history: when it was licensed, rating and route changes, and when it last offered sponsorship in an advert.

Unlock with Pro

About Accession Therapeutics Limited

Accession Therapeutics Limited is a biotechnology and healthcare company focused on the development of novel immuno-oncology therapeutics. The business researches and designs targeted cancer treatments that combine high specificity and potency to counter tumour diversity.

By developing these advanced therapies, the company aims to improve the effectiveness of cancer treatments. Its research operations focus on engineering therapeutic candidates that can precisely target cancer cells while sparing healthy tissue.

Open roles

1 live position matched to this sponsor licence.